According to Fortune Business Insights, the global uterine fibroid drugs market was valued at USD 2.97 billion in 2025 and is projected to grow from USD 3.38 billion in 2026 to USD 9.71 billion by 2034, reflecting a CAGR of 16.28% over the forecast period. North America led the market in 2025, holding a 45.56% share.
Uterine fibroids — also called leiomyomas or myomas — are benign, non-cancerous growths of smooth muscle and connective tissue that form in or on the uterine walls, and can be symptomatic or asymptomatic, with symptomatic cases causing heavy bleeding, pelvic pain, anemia, urinary issues, and fertility complications.
Growth Drivers
The report attributes market expansion primarily to the rising prevalence of fibroids, with lifestyle factors such as sedentary habits, obesity, and delayed menopause acting as key risk contributors. Notably, the analysis cites NIH data indicating that fibroids affect up to 70% and 80% of white women and women of African ancestry respectively over their lifetimes, with roughly 30% of these women developing severe symptoms requiring medical care.
Growing preference for non-invasive management is also a factor, since many patients and clinicians favor drug-based approaches over surgery to shrink fibroids and manage symptoms, with advances in molecular biology opening the door to more targeted therapies. The report also references a 2025 Vanderbilt University Medical Center study that identified new genes linked to uterine fibroids, potentially enabling next-generation, personalized treatments.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/uterine-fibroid-drugs-market-114341
Restraints and Challenges
A significant restraint is treatment tolerability: side effects such as bone density loss, hot flashes, and cardiovascular risks often cause patients to discontinue therapy early, and regulators frequently limit approvals to shorter treatment durations as a result. As an example, the report notes that in AbbVie's ELARIS UF-1 and UF-2 trials for ORIAHNN, roughly 10% of participants stopped treatment due to adverse reactions.
Regulatory stringency compounds this challenge, since women's health therapies require extensive long-term safety data given fertility and hormonal considerations, and agencies closely scrutinize risks like bone density loss and cardiovascular events — a process that raises development costs and slows innovation, particularly for smaller biopharma firms.
Segment Insights
By drug class, GnRH agonists are expected to lead with a 54.18% share in 2026, largely due to their broad global availability for rapid fibroid shrinkage and bleeding control, while GnRH antagonists are set to post strong CAGR growth on the back of expanding pharma pipelines.
By fibroid type, intramural fibroids are projected to hold 53.40% share in 2026, as they are the most common presentation and are closely linked to heavy bleeding, pelvic pain, and fertility issues.
By route of administration, the parenteral segment is expected to dominate with a 72.72% share in 2026 due to rising adoption of injectables and sustained-release formulations, while the oral segment is set to grow at 29.5% thanks to ease of use and better adherence.
By application, the shrinkage segment is projected to lead with a 56.42% share in 2026, since therapies that actively reduce fibroid volume provide both symptom relief and disease modification, reducing reliance on surgery.
By distribution channel, retail pharmacies and drug stores dominated in 2024, owing to their role in dispensing approved GnRH antagonists and their broad accessibility for chronic medication management.
Regional Outlook
North America contributed 45.56% of the global market in 2025 at USD 1.35 billion, and is projected to reach USD 1.54 billion in 2026, supported by strong healthcare infrastructure and high pharmaceutical R&D activity. Europe accounted for USD 0.77 billion in 2025 (26.08% share), projected to reach USD 0.87 billion in 2026, driven by rising diagnosis rates and favorable reimbursement policies. Asia Pacific stood at USD 0.61 billion in 2025 (20.44% share), estimated to reach USD 0.7 billion in 2026.
Competitive Landscape
The report describes the market as semi-consolidated, with major players including AbbVie Inc., Neurocrine Biosciences, Inc., Sumitomo Pharma Co., Ltd., and Pfizer Inc. gaining share through mergers, acquisitions, collaborations, and sustained R&D investment. Other companies profiled include Kissei Pharmaceutical, ObsEva SA, TiumBio Co., Ltd., and Daewon Pharmaceutical Co., Ltd.
Recent developments cited in the report include Knight Therapeutics' October 2025 relaunch of MYFEMBREE in Canada and Searchlight Pharma's collaboration with Apotex to secure Canadian rights to linzagolix.